பிரதா தடுப்பு மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிரதா தடுப்பு மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிரதா தடுப்பு மருந்துகள் Today - Breaking & Trending Today

Novavax's Effort to Vaccinate the World, From Zero to Not Quite Warp Speed


Jul 20, 2021
On a sweltering June morning, Novavax CEO and covid vaccine maker Stanley Erck stood on a stage unmasked and did something that would have been unthinkable six months ago: He shook hands with Maryland’s governor.
Erck was with Gov. Larry Hogan to announce Novavax’s global vaccine headquarters ― a campus expected to house laboratories and more than 800 employees. Hogan called Novavax’s future “bright” and marveled that more than 71% of the state’s adults had received at least one shot.
None of those was a Novavax vaccine, which is still unavailable for the American public due to delayed clinical trial results and other difficulties. Hogan, for his part, received his first vaccine dose ― made by fellow biotech upstart Moderna ― in January. ....

New York , United States , North Carolina , United Kingdom , Czech Republic , National Institutes Of Health , South Korea , John Kutney , Christine Jackman , Gerry Farrell , Larry Hogan , John Trizzino , Stanley Erck , Rachana Pradhan , Prashant Yadav , Dawd Siraj , Gregory Glenn , Charles Duncan , Joe Biden , Fred Shemer , Sarah Jane Tribble , Fujifilm Jackman , Global Development , Department Of Defense , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations ,

Big pharma and private equity seek healthy returns in Europe's east


Big pharma and private equity seek healthy returns in Europe’s east
WARSAW/PRAGUE (Reuters) – In the race to supply vaccines to end the COVID-19 pandemic, U.S. drug developer Novavax turned to emerging Europe to speed up production with a pair of deals that endorsed a growing trend for consolidation in the region.
As part of a doubling in merger activity, buoyed by a combination of private equity and big pharma, Novavax bought the Praha Vaccines factory near Prague in a $167 million transaction last May. It followed up by partnering with Polish biotech company Mabion in March.
The pharmaceutical industry focused around Czech Republic, Hungary and Poland is dwarfed by that of nearby Germany, but industry insiders and analysts see scope for growth based on moderate costs and an expectation of higher healthcare spending, as well as a scientifically educated workforce. ....

Czech Republic , Milosz Gruca , Praha Vaccines , Croatian Fidelta , செக் குடியரசு , பிரதா தடுப்பு மருந்துகள் ,